Brazil Antifungal Drugs Market Size & Outlook, 2023-2030
Brazil antifungal drugs market, 2018-2030 (US$M)
Related Markets
Brazil antifungal drugs market highlights
- The Brazil antifungal drugs market generated a revenue of USD 184.0 million in 2023 and is expected to reach USD 262.6 million by 2030.
- The Brazil market is expected to grow at a CAGR of 5.2% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 184.0 million |
| Market revenue in 2030 | USD 262.6 million |
| Growth rate | 5.2% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Brazil accounted for 1.2% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 262.6 million by 2030.
Azoles was the largest segment with a revenue share of 48.53% in 2023. Horizon Databook has segmented the Brazil antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
A significant number of Brazilians face the risk of serious fungal infections due to associated comorbidities, such as transplant recipients, cancers, asthma, HIV infections, and prior tuberculosis. These comorbidities can make infections difficult to treat.
Key players operating in the market are focusing on product launches and geographic expansion in the country to remain competitive.
For instance, in October 2019, Basilea Pharmaceutica Ltd. collaborated with Grupo Biotoscana S.L. and received regulatory approval and marketing authorization for Cresemba, an antifungal isavuconazole class of drug, in Brazil.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil antifungal drugs market size, by drug class, 2018-2030 (US$M)
Brazil Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
